A detailed history of Sargent Bickham Lagudis LLC transactions in Seagen Inc. stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 41 shares of SGEN stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41
Previous 41 -0.0%
Holding current value
$0
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 05, 2021

SELL
$142.45 - $169.82 $28,489 - $33,964
-200 Reduced 82.99%
41 $7,000
Q4 2020

May 24, 2021

BUY
$164.63 - $211.93 $39,675 - $51,075
241 New
241 $33,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Sargent Bickham Lagudis LLC Portfolio

Follow Sargent Bickham Lagudis LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.